{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:27:38Z","timestamp":1749655658308,"version":"3.40.5"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.anai.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T16:20:56Z","timestamp":1707582056000},"page":"652-653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of drug-induced hypersensitivity syndrome associated with levetiracetam and clobazam is likely underreported"],"prefix":"10.1016","volume":"132","author":[{"given":"Nikhita R.","family":"Kichili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-0227","authenticated-orcid":false,"given":"Alyssa","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dheeraj","family":"Kagithala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayezel Munoz","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wilkerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2024.02.003_bib0001","unstructured":"FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (ONFI, Sympazan). U.S. Food and Drug Administration. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr. Accessed December 26, 2023"},{"issue":"2","key":"10.1016\/j.anai.2024.02.003_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/0019-5154.177777","article-title":"Levetiracetam induced drug reaction with eosinophilia and systemic symptom syndrome","volume":"61","author":"Dar","year":"2016","journal-title":"Indian J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2024.02.003_bib0003","first-page":"e4245","article-title":"A rare case of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome with cholecystitis in a patient on levetiracetam","volume":"11","author":"Singh","year":"2019","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.anai.2024.02.003_bib0004","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/PEC.0000000000001754","article-title":"A drug reaction with eosinophilia and systemic symptoms syndrome associated with clobazam","volume":"36","author":"Manyas","year":"2020","journal-title":"Pediatr Emerg Care"},{"issue":"5","key":"10.1016\/j.anai.2024.02.003_bib0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.anai.2024.02.003_bib0006","unstructured":"TriNetX, LLC. Available at: https:\/\/trinetx.com. Accessed January 21, 2024"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T23:31:47Z","timestamp":1715297507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1081120624000796"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.02.003","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of drug-induced hypersensitivity syndrome associated with levetiracetam and clobazam is likely underreported","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}